Where does Alectos Therapeutics Inc. rank among US patent assignees?

According to USPTO PatentsView (2015–2025 granted utility patents), Alectos Therapeutics Inc. ranks #15,803 of 49,997 assignees by granted-patent volume, the same sort as the companies listing and top-holders ranking. See /methodology/#corpus-placement.

How many patents does Alectos Therapeutics Inc. hold?

Alectos Therapeutics Inc. holds 18 US utility patents granted between 2015 and 2022, spanning 10 technology areas.

What is Alectos Therapeutics Inc.'s Innovation Score?

Alectos Therapeutics Inc. has an Innovation Score of 37.3 out of 100 (top 44% of the corpus). This composite metric weighs portfolio volume (40%), grant velocity (20%), technology breadth (25%), and claim depth (15%).

What technology areas does Alectos Therapeutics Inc. focus on?

Alectos Therapeutics Inc.'s top technology area is C07D (Heterocyclic Compounds) with 17 patents, ranking #514 of 3,165 assignees active in that subclass. Grants appear in 10 CPC subclasses total.

Is Alectos Therapeutics Inc.'s patent grant rate increasing or decreasing?

Alectos Therapeutics Inc.'s recent grant velocity is -87% compared to the prior five-year period (grant years, not application filing dates). Grant activity has slowed relative to earlier years.

What does claim depth mean for Alectos Therapeutics Inc.'s patents?

Alectos Therapeutics Inc.'s patents average 15.5 claims each. This is an aggregate descriptive count from the grant record; it does not establish claim scope, legal strength, enforceability, or design-around risk.

How is the Alectos Therapeutics Inc. patent data sourced?

All patent data comes from USPTO PatentsView, a public research dataset maintained by the United States Patent and Trademark Office covering US granted utility patents from 2015 to 2025.

USPTO 2015–2025 USPTO PatentsView Foreign Corporation

Alectos Therapeutics Inc.

USPTO PatentsView assignee record - 18 granted patents across 10 technology areas, recorded in grant years 2015–2022. Grant-trend analysis is cross-referenced to USPTO Patent Public Search; it does not measure application filings, current R&D, or legal strength. Primary class: C07D (Heterocyclic Compounds).

Compiled by PlainPatent · May 15, 2026

RSS updates for this company

Explore the portfolio See the ranking

The verdict

According to USPTO PatentsView, Alectos ranks #15,803 of 49,997 tracked US assignees by granted-patent volume, with 18 patents across 10 technology areas.

#15,803
of 49,997 US assignees by volume: Top 44%
by Innovation Score (37.3/100): 15.5
avg claims per patent: -87%
grant velocity, last 5 yrs

USPTO PatentsView assignee plate

Corpus R15803 · Foreign Corporation #15,803 · 18 grants

GRANTS-MICRO · MID-PACK · PHOTO-FINISH · CPC-FOCUS · INNOV-THIN · CLAIMS-RICH · TYPE-FRNCORP · VEL-DROP · BOOK-FULL

GRANTS-MICRO 18 grants
MID-PACK #15,803/49,997
PHOTO-FINISH Aegis Therapeutics
CPC-FOCUS C07D · 10 areas
INNOV-THIN 37.3/100
CLAIMS-RICH 15.5 claims/avg
TYPE-FRNCORP Foreign Corp
VEL-DROP -87% vel
BOOK-FULL 10/10 fields

Nearest grant-volume peer: Aegis Therapeutics, LLC (±0 grants)

Instrument codes from this assignee’s USPTO PatentsView grant sheet: volume band, corpus rank, photo-finish peer, lead CPC, Innovation Score, claim depth, assignee type, velocity, and book completeness. Not a USPTO rating of patent strength.

How Alectos’s 37.3 Innovation Score adds up

The same four weighted components behind every Innovation Score on PlainPatent: portfolio volume, grant velocity, technology breadth, and claim depth.

Volume 10.2 pts (27%) Velocity 6.7 pts (18%) Breadth 11.2 pts (30%) Claim depth 9.3 pts (25%)

Qualcomm Incorporated · highest

85
Alectos Therapeutics · this assignee

37
3D Lighting… · lowest

7

What this shows Alectos's Innovation Score is 37.3/100 (top 44% of the PatentsView-derived corpus). The chart places that score against the nearest Innovation Score peers plus corpus poles, not a reprint of the volume ranking.

Does more volume mean deeper claims for Alectos?

Each dot is one of Alectos’s 8 nearest volume peers (same corpus rank neighbourhood as the chart above), placed by total granted patents (horizontal) against average claims per patent (vertical). Alectos’s own 15.5 claims/patent is at or below the 16.2 median for these volume peers. Volume here does not track with deeper claims; several lower-volume peers claim more thoroughly per patent.

Alectos vs its 8 nearest volume peers: granted patents vs average claims per patent. Source: USPTO PatentsView.

Where Alectos's grants concentrate

Alectos Therapeutics Inc. is a focused PatentsView assignee: 10 CPC subclasses with 94.4% of grants classified under C07D (Heterocyclic Compounds). Peak complete grant year is 2017 (8 grants) versus a trough of 1 in 2021. By volume, Alectos sits between Aegis Therapeutics, LLC and Apex Biotechnology Corp..

Alectos's three-year grant acceleration

Alectos Therapeutics Inc. shows 1 grants in 2022–2024 against only 1 in 2019–2021. That prior window is too thin for a growth multiple (rename and spin-out assignees look artificially high when the baseline is near zero), so PlainPatent withholds a ranked acceleration claim here.

Aegis Therapeutics

18
AFL IG

18
Ahlstrom OYJ

18
Airgap Networks

18
Ambit Biosciences

18
Anexa Labs

18
AOI

18
Apex Biotechnology

18
Alectos Therapeut… ◀

18

What this shows Alectos holds 18 patents at rank #15,795, shown against the 8 assignees closest to it in grant volume rather than the industry's largest filers.

Companies ranked near Alectos

By rank, the assignees closest to #15,795 in granted patent volume.

Leaders in C07D (Heterocyclic Compounds)

Other assignees with the most granted patents in Alectos's primary technology class.

Alectos's Innovation Score vs. every tracked assignee

Composite of portfolio volume, grant velocity, technology breadth, and claim depth (0–100)

37 Top 44% higher than 56% of 49,997 US assignees

Each bar is a band; taller bars hold more US assignees. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count, share, and where it sits relative to this entry.

Source USPTO PatentsView, PlainPatent Innovation Score · 2015–2025

USPTO utility patent grants by year · 2015–2022

Grants by year

Teal-shaded recent years (2020–present) versus the 2015–2019 baseline. Full figures in the table below.

View data table

Alectos Therapeutics Inc. patent grants by year, 2015–2025
Year	Patents Granted	Share of Period
2015	3	16.7%
2016	3	16.7%
2017	8	44.4%
2018	2	11.1%
2021	1	5.6%
2022	1	5.6%

Which technologies does Alectos Therapeutics Inc. patent most?

C07D - Heterocyclic Compounds 17

A61P - Specific Therapeutic Activity OF Chemical Compounds OR Medicinal Preparations 13

C07H - SUGARS; Derivatives THEREOF; NUCLEOSIDES; NUCLEOTIDES; Nucleic Acids 8

C12Q - Measuring OR Testing Processes Involving Enzymes, Nucleic Acids OR Microorganisms ; Compositions OR Test Papers THEREFOR; Processes OF Preparing Such COMPOSITIONS; Condition-responsive Control IN Microbiological OR Enzymological Processes 7

G01N - Investigating OR Analysing Materials BY Determining Their Chemical OR Physical Properties 6

A61K - Preparations FOR Medical, Dental OR Toiletry Purposes 4

C12Y - Enzymes 2

C12N - Microorganisms OR ENZYMES; Compositions THEREOF; Propagating, Preserving, OR Maintaining MICROORGANISMS; Mutation OR Genetic ENGINEERING; Culture Media 2

B65D - Containers FOR Storage OR Transport OF Articles OR Materials, e.g. Bags, Barrels, Bottles, Boxes, Cans, Cartons, Crates, Drums, Jars, Tanks, Hoppers, Forwarding CONTAINERS; Accessories, Closures, OR Fittings THEREFOR; Packaging ELEMENTS; Packages 1

C07B - General Methods OF Organic CHEMISTRY; Apparatus Therefor 1

Top 10 of 10 technology areas

More on this record

Data Source

USPTO PatentsView, US granted patents 2015–2025

View all rankings → How is Innovation Score calculated?

What to do with this data

Alectos Therapeutics Inc.'s patent record in context - here's where to go next.

Alectos Therapeutics Inc.'s lead technology class is C07D (Heterocyclic Compounds), 94.4% of its portfolio - see every assignee active in that class. Explore C07D
Ranked #15,803 of 49,997 tracked assignees by patent volume - see the full leaderboard. See the ranking
Compare Alectos Therapeutics Inc. against Aegis Therapeutics, LLC, an assignee filing at a similar volume. Compare portfolios
Innovation Score of 37.3/100 blends volume, velocity, technology breadth, and claim depth. How it's calculated

Figures reflect USPTO PatentsView grant data through May 2026; pending applications not yet granted are not counted.

Data sourced from USPTO PatentsView - official U.S. government patent data. See our methodology for computation details. Retrieved and formatted by PlainPatent

Disclaimer: This information is provided for informational purposes only and does not constitute professional advice. Data is sourced from the USPTO PatentsView database. Consult a qualified professional before making decisions based on this data.

Read our methodology - how this data is sourced, computed, and verified.

Data sources used on this page

USPTO PatentsView - the disambiguated bulk patent-grant, assignee, and CPC data this page's figures are derived from. patentsview.org
Cooperative Patent Classification (CPC) - the joint USPTO/EPO classification scheme used to group patents by technology area. cooperativepatentclassification.org
USPTO Patent Public Search - the official interface to verify the status of any individual patent. ppubs.uspto.gov

Compiled by PlainPatent, US Patent Intelligence Editorial Process · May 15, 2026

Every figure on PlainPatent is rendered directly from USPTO source data, no number is typed in by an editor. This page draws directly on USPTO source data, no figure is typed in by an editor. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error. Data current as of May 2026.